Myriad Genetics, Inc.

NASDAQ:MYGN

Medical - Diagnostics & Research

Healthcare
$5.53 +3.20%

+$0.14 today

Market cap
$530.45M
Beta
1.64
P/E (TTM)
-1.1
EPS (TTM)
-$4.27
52W Low $3.53High $8.59

Volume 1.26M

Average 1.81M

MYGN Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Myriad Genetics, Inc.NASDAQ: MYGN

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin narrows to -17.0%

Net margin was -17.0% in Q1 FY2026, down 17.0 pp from a year earlier. On a trailing-twelve-month basis it was -48.2%, down 36.0 pp year over year. Over 3 fiscal years it narrowed by 27.9 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 5 analysts of -8.4% for the fiscal year ending Dec 2026, up from -44.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-17.0%-13.3 pp QoQ
Last fiscal yearDec 2025
-44.4%-29.2 pp YoY
LTMMar 2026
-48.2%-36.0 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-17.0 pp+152.9 pp+169.9 pp
1 year-29.2 pp+36.0 pp+65.1 pp
3 years-27.9 pp+34.7 pp+62.6 pp
5 years+31.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-44.4%
Year-over-year change
-29.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How MYGN compares with its peers on the latest reported figures

  • MYGN's LTM Mar 2026 net margin of -48.2% is the 8th highest of the 10 companies compared; the peer median is -7.1%.
  • Its year-over-year change of -36.0 pp is the 8th highest of 10, against a peer median of +5.8 pp.
  • Over three fiscal years its change of -27.9 pp compares with a peer median of +25.2 pp.
MYGN Competitors Peer median
Net Margin for MYGN and competitors
Company Period LTM level YoY 3-year change
VCYTVeracyte, Inc.LTM Jun 202620.4% +14.9 pp+25.2 pp
QGENQiagen N.V.LTM Jun 202619.5% +1.2 pp+0.6 pp
BLLNBillionToOne, Inc.LTM Jun 20268.4% +23.1 pp—
NEONeoGenomics, Inc.LTM Jun 2026-6.8% +8.3 pp+13.4 pp
NTRANatera, Inc.LTM Jun 2026-7.1% +5.8 pp+57.8 pp
FLGTFulgent Genetics, Inc.LTM Mar 2026-23.0% -9.1 pp-41.9 pp
GHGuardant Health, Inc.LTM Sep 2026-37.9% +6.3 pp+103.2 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-48.2% -36.0 pp-27.9 pp
PSNLPersonalis, Inc.LTM Mar 2026-148.1% -50.0 pp—
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026-2454.6% -940.1 pp+6371.3 pp
Peer median (excluding MYGN) -7.1%+5.8 pp+25.2 pp

Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue690.6M678.4M753.2M837.6M824.5M
Cost of Revenue197.6M202M236.2M252.2M247.9M
Gross Profit493M476.4M517M585.4M576.6M
Gross Margin71.4%70.2%68.6%69.9%69.9%
Research & Development81.9M85.4M88.7M113.4M106.8M
Selling, General & Admin537.8M514.7M572.9M560M537.6M
Operating Expenses683.5M617M774.4M708.9M644.4M
Depreciation & Amortization62.8M52.7M61.9M61.2M53.7M
EBITDA12.3M(84.7M)(197.4M)(59.5M)(330.9M)
EBITDA Margin1.8%-12.5%-26.2%-7.1%-40.1%
Operating Income(190.5M)(140.6M)(257.4M)(123.5M)(67.8M)
Operating Margin-27.6%-20.7%-34.2%-14.7%-8.2%
Interest Income700K2.6M2.5M1.7M1.8M
Interest Expense6.6M3.2M2.9M2.8M10.5M
Other Income / Expenses133.4M(16.9M)(4.8M)(35.5M)(327.3M)
Income Before Tax(57.1M)(140.6M)(262.2M)(123.5M)(395.1M)
Pre-Tax Margin-8.3%-20.7%-34.8%-14.7%-47.9%
Income Tax Expense(29.9M)(28.6M)1.1M3.8M(29.2M)
Net Income(27.2M)(112M)(263.3M)(127.3M)(365.9M)
Net Margin-3.9%-16.5%-35.0%-15.2%-44.4%
EPS (Basic)(0.35)(1.39)(3.18)(1.41)(3.96)
EPS (Diluted)(0.35)(1.39)(3.18)(1.41)(3.96)
Weighted Avg Shares77.71M80.58M82.8M90.6M93.3M
Weighted Avg Shares (Diluted)78M80.6M82.8M90.6M93.3M

Myriad Genetics, Inc.

NASDAQ:MYGN

Intrinsic Alpha fair value

Locked

Current Price

$5.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.